GLP-1 Dropout Rates Signal Real-World Implementation Problems

What They Found

This analysis examined real-world discontinuation patterns for GLP-1 receptor agonists and tirzepatide. The study tracked patients who stopped treatment and identified the primary drivers of discontinuation along with metabolic consequences of stopping therapy.

Why It Matters

Clinical trials paint an optimistic picture of GLP-1 adherence that doesn't match clinical reality. The controlled environment of studies masks the practical barriers patients face — cost, side effects, and lifestyle factors that drive discontinuation rates well above what we see in published efficacy data.

The compounds involved — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — work through distinct but overlapping mechanisms. Semaglutide targets GLP-1 receptors exclusively, while tirzepatide hits both GLP-1 and GIP receptors. This dual mechanism typically produces better weight loss and glucose control, but it doesn't necessarily translate to better real-world persistence.

What's particularly concerning is the metabolic rebound that occurs post-discontinuation. Most patients regain significant weight within 6-12 months of stopping, often returning to baseline or worse. This isn't just about willpower — these medications fundamentally alter appetite signaling and gastric emptying, and those effects disappear when treatment stops.

What I'd Watch For

Without access to the full methodology, I can't assess how they defined discontinuation or controlled for different patient populations. Insurance coverage patterns, which vary dramatically by region and plan, likely skew these numbers significantly.

The real question is whether the discontinuation drivers are addressable. If it's primarily cost-related, we're looking at a healthcare access problem. If it's side effects, we need better titration protocols and patient education. The study needs to stratify by reason for discontinuation to be clinically useful.

Bottom Line

This data should inform realistic expectations about long-term GLP-1 therapy adherence. Don't base protocols on clinical trial completion rates — plan for real-world dropout patterns and have metabolic maintenance strategies ready.